Eli Lilly (LLY) Stock Climbs as China Approves First GLP-1 Weight-Loss Pill

TLDR Eli Lilly (LLY) stock hit a record high in premarket trading Thursday, up nearly 3%. China approved orforglipron, sold as Foundayo, as its first GLP-1 weight-loss pill. Novo Nordisk’s oral Wegovy is still waiting on a Chinese decision. J.P. Morgan sees China’s GLP-1 weight-management sales reaching 30 billion yuan ($4.5 billion) in five to [...]

The post Eli Lilly (LLY) Stock Climbs as China Approves First GLP-1 Weight-Loss Pill appeared first on Blockonomi.